DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes.
Several cancer-related genes have been discovered and molecular test for the cancer genetic risk assessment has been widely increasing. Disorders such as Multiple Endocrine Neoplasia syndromes have received benefits from the identification of the responsible genes whose mutations account for the genetic susceptibility to develop endocrine tumours. Primary hyperparathyroidism (PHPT)is a clinical phenotype frequently associated to Multiple Endocrine Neoplasia syndromes, but it can also represent the unique endocrinopathy recurring as a familial cluster. In recent years, care options have been made available to patients and families with hereditary PHPT, and the process of systematically assessing the genetic risk has been becoming increasingly important. This review aims to help health providers not frequently dealing with genetic testing use and it will introduce some general concepts concerning genetic diagnosis issues. As an example the role and the practical usefulness of DNA-based diagnosis in patients affected by different forms of congenital PHPT is described, with a close look on why, when and how genetic testing should be performed in these subjects and their relatives. Some practical recommendations and suggestions concerning on how to deal when a suspect or known case of familial PHPT has to be faced conclude this manuscript.
Falchetti
A
A
The Regional Centre for Hereditary Endocrine Tumors, Unit of Metabolic Bone Diseases, University Hospital of Careggi, Italy.
Marini
F
F
Giusti
F
F
Cavalli
L
L
Cavalli
T
T
Brandi
M L
ML
D004273:DNA, Neoplasm / Q000235:genetics; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000175:diagnosis* / Q000235:genetics; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis / Q000235:genetics; D009154:Mutation; D010641:Phenotype
D004273:DNA, Neoplasm